Prescribing and monitoring of riluzole in amyotrophic lateral sclerosis: a retrospective cohort study from Health New Zealand – Te Whatu Ora Waitaha Canterbury
Rattachement africain : nz. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AIM: This retrospective cohort study assessed adherence to the Motor Neurone Disease New Zealand best practice guidelines and Pharmac Special Authority criteria for riluzole in a Canterbury-based amyotrophic lateral sclerosis (ALS) cohort. Secondary objectives included reasons for not prescribing, side effects and treatment initiation relative to diagnosis. METHOD: A retrospective cohort study was conducted using the Christchurch Hospital respiratory department's ALS database. Patients diagnosed between January 2020 and November 2024 were included. Electronic health records and Special Authority records were reviewed. Patients with incomplete data or non-motor neurone disease (MND) diagnoses were excluded. RESULTS: Of 115 patients, 69 (60%) were prescribed riluzole. Less than 45% of patients had baseline blood tests, and pre-treatment spirometry was completed in 70% of patients. Delays in prescribing improved rates of baseline spirometry, but not blood test completion. Ongoing monitoring was poor, with less than 60% of patients completing recommended tests across all time points. Eight patients (11.6%) reported side effects, and three discontinued treatment following alanine aminotransferase derangement. CONCLUSION: Adherence to recommended monitoring and Special Authority criteria for riluzole was inconsistent in this cohort. In the context of emerging evidence supporting broader survival benefit and reduced drug cost, further evaluation of current Special Authority prescribing criteria may be warranted.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prescribing and monitoring of riluzole in amyotrophic lateral sclerosis: a retrospective cohort study from Health New Zealand – Te Whatu Ora Waitaha Canterbury
- Date Crossref
- 14/08/2026
- Éditeur
- Pasifika Medical Association Group
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Waitaki Biosciences (New Zealand) pays non établi dans la noticeEntreprise
-
Health New Zealand pays non établi dans la noticeÉtablissement de santé
-
Canterbury Health Laboratories pays non établi dans la noticeStructure de recherche
-
Environment Canterbury pays non établi dans la noticeOrganisme public
-
House Officer pays non établi dans la noticeInstitution
-
Clinical Director Palliative Care pays non établi dans la noticeÉtablissement de santé
-
Palliative Medicine Physician pays non établi dans la noticeInstitution
Waitaki Biosciences (New Zealand), Health New Zealand et Canterbury Health Laboratories, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.